- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05661006
ETOL-Elderly Study of the Efficiency of the Innovative Food Supplement in Elderly Adults (ETOL-Elderly)
Study of the Efficiency of the Innovative Food Supplement in Improving Nutritional Status of Elderly Adults
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Trzin, Slovenia
- Vizera
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Subject Informed consent form (ICF) is singed
- Aged at least 65 at the time of the signature of ICF
- A body mass index lower than 32 kg/m2
- Willing to avoid a consumption supplementation with protein, vitamin D and vitamin B12 during the study
- Willing to follow all study procedures, including attending all site visits (including blood sampling) and keeping a diary for using the product and six 24-hour dietary records (3x pre-intervention, 3x during last week of the intervention)
Exclusion criteria:
- Medical treatment with Vitamin D and/or Vitamin B12
- Supplementation with protein, vitamin D and/or vitamin B12 during least 2 months
- Known drug and/or alcohol abuse
- Known lactose/gluten intolerances/food allergies
- Inadequate veins (in the opinion of the investigator) or known contraindication for venous blood withdrawal
- Have chronic bowel disease (ulcerative colitis, Chron's disease, stomach or duodenal ulcer, chronic inflammation of the stomach or duodenum)
- Have acute gastrointestinal infection with vomiting and / or diarrhea
- Have planned general anaesthesia or colonoscopy at the time of the study
- Have malabsorption syndrome
- Less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)
- Have stomach or bowel resection
- Do not have neat and functional teeth
- Take regular or occasional laxative products
- Use antacids (Rupurut / Rutacid / Talcit)
- Mental incapacity that precludes adequate understanding or cooperation
- Participation in another investigational study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control group
Subjects taking control product
|
On day 1 subjects start with intervention on prearranged day.
First dosage of test product is consumed during day 1 between regular meals (not as meal substitute).
In the following days: continuation of consumption of test product once per day until end
|
Experimental: Active group
Subjects taking active product
|
On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day). Intervention end on day 56 ±3 (fasted condition): Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight & height Collecting data regarding the palatability of the product |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in serum vitamin D levels will be determined
Time Frame: 56 days
|
Serum level of 25-OH-vitamin D will be measured before and after the intervention for each individual.
|
56 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in dietary protein intake will be determined
Time Frame: 56 days
|
Dietary protein intake will be estimated before and after the intervention for each individual, using 3x24h food records.
|
56 days
|
Change in serum vitamin B12 levels will be determined
Time Frame: 56 days
|
Serum level of vitamin B12 will be measured before and after the intervention for each individual.
|
56 days
|
Malnutrition at baseline
Time Frame: baseline
|
Risks for malnutritition at baseline will be assessed using dietary records (3x24h food record: energy, protein and plasma concentration of 25-OH-D and vitamin B12.
|
baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mojca Miholič, MD, Researcher
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020/1-ET-SK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin B 12 Deficiency
-
Washington University School of MedicineUniversity of California, Davis; Universidad San Francisco de Quito; Pan American...CompletedCholine Deficiency | Vitamin B-12 Deficiency | Lipids Deficiency | Amino Acids DeficiencyEcuador
-
USDA, Western Human Nutrition Research CenterCompletedAchlorhydria | Vitamin B-12 DeficiencyUnited States
-
Liaquat University of Medical & Health SciencesNot yet recruitingVitamin B 12 DeficiencyPakistan
-
University Children's Hospital, ZurichActive, not recruitingVitamin B 12 DeficiencyAustria, Germany
-
University of British ColumbiaDairy Farmers of CanadaCompletedVitamin B 12 DeficiencyCanada
-
Haukeland University HospitalNorwegian Foundation for Health and Rehabilitation; Foundation to Promote Research...CompletedVitamin B 12 DeficiencyNorway
-
Sykehuset Innlandet HFUniversity of Oslo; University of Bergen; Inland Norway University of Applied...Recruiting
-
University Hospital, Basel, SwitzerlandCompleted
-
Marmara UniversityCompleted
-
Gerencia de Atención Primaria, MadridInstituto de Salud Carlos IIICompleted
Clinical Trials on Use of placebo food supplement
-
Medecins Sans Frontieres, NetherlandsCompletedWeight Loss | Malaria | Weight Gain | ConvalescenceCongo
-
University of East AngliaCompletedCardiovascular Disease Risk ReductionUnited Kingdom
-
AB Biotics, SACompleted
-
University of AthensRecruitingCOVID-19 | Endothelial DysfunctionGreece
-
Pharmanutra S.p.a.NEA Clinical S.r.l.CompletedPrimary Knee Osteoarthritis Grade 3 - 4Georgia
-
University of AthensRecruiting
-
University of LimerickCompletedCardiovascular DiseasesIreland
-
Arafarma Group, S.A.Completed
-
University of East AngliaNot yet recruitingInsomnia | Sleep Disturbance
-
AB Biotics, SACentre for the Development of Industrial Technology, Ministry of Science...RecruitingMicrobial ColonizationSpain